Navigation Links
Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
Date:4/27/2013

NANJING, China, April 27, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, announced today that the Company filed its annual report on Form 20-F for the year ended December 31, 2012 with the Securities and Exchange Commission on April 26, 2013, U.S. Eastern Time. The annual report can be accessed on the Company's investor relations website at http://ir.simcere.com. The Company will provide a hard copy of the annual report containing its audited financial statements for the year ended December 31, 2012, free of charge, to its shareholders and ADS holders upon request.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ("Simcere") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:

Email: ir@simcere.com

In Nanjing:

Jie Liu D'Elia

Vice President

Simcere Pharmaceutical Group

Tel: 86-25-8556-6666*8857


'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
2. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
3. Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere Vaxtec
4. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Legal Counsel
5. Simcere Pharmaceutical Group Announces Receipt of "Going Private" Proposal
6. Simcere Pharmaceutical Group Reports Preliminary Unaudited Fourth Quarter And Full Year 2012 Results
7. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Thursday, March 7, 2013
8. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
9. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
10. Simcere Pharmaceutical Group to Announce Third Quarter 2012 Financial Results on Thursday, November 15, 2012
11. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... ST. LOUIS, July 29, 2014  Express Scripts Holding ... quarter net income attributable to Express Scripts stockholders of ... per diluted share, as detailed in Table 4, was ... "We are well positioned to serve our clients with ... and to improve the health outcomes of our members," stated ...
(Date:7/29/2014)... 2014  EnteroMedics Inc. (NASDAQ: ETRM ), ... treat obesity, metabolic diseases and other gastrointestinal disorders, today ... Thursday, August 7, 2014 at 11:00 AM Eastern Time ... June 30, 2014 and to provide a business update. ... quarter conference call may be accessed by dialing (877) ...
(Date:7/29/2014)... 2014 New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. The study finds that the ...
Breaking Medicine Technology:Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 30Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 31EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... April 14, 2011 Oxford Finance Corporation (Oxford), a ... a $2 million equipment loan with Synta Pharmaceuticals Corp. ... compounds for use in Synta,s ongoing clinical trials in ... "Synta Pharmaceuticals has a diverse drug pipeline, including ...
... (NYSE: BT ) shared its vision of ... cloud computing strategies to pharma research at the Bio-IT ... This vision reflects BT,s strong capabilities and increasing specialization ... world,s leading pharmaceutical companies rely on BT to support ...
Cached Medicine Technology:Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2BT Pushes for R&D Innovation at Bio-IT World Conference 2BT Pushes for R&D Innovation at Bio-IT World Conference 3
(Date:7/29/2014)... 2014 Summer is here, and that means it’s ... hike, swimming in a pool or laying out on the beach. ... ticks. The Puppy Store is here to help pet owners protect ... It’s almost impossible to completely keep fleas and ticks at bay, ... chances of their pets coming into contact with fleas and ticks. ...
(Date:7/29/2014)... 2014 A team of scientists, led ... PhD, has developed a blood test for Alzheimer’s disease ... development of Alzheimer’s disease interventions, according to an article ... puzzle, and this study represents one of several pieces ... past couple of years,” Ethell said. , The study, ...
(Date:7/29/2014)... cure most cases of cancer is to surgically remove ... is that the surgeon may fail to extract the ... a new technique, researchers at the University of Pennsylvania ... the entire tumor in the patient, increasing the likelihood ... injectable dye that accumulates in cancerous tissues much more ...
(Date:7/29/2014)... 29, 2014 As testosterone treatment lawsuits ... Bernstein Liebhard LLP notes that a new study is ... Type 2 diabetes. The research, which was published online ... June 30th, involved 88 men who suffered from Type ... aging male symptoms and erectile dysfunction. Roughly half of ...
(Date:7/29/2014)... Gerontological Society of America (GSA) and the National ... MD, PhD, of Columbia University as the 2014 recipient ... and Aging. , This award recognizes and honors the ... the field of creativity and aging shifted the conceptual ... and potential. Cohen inspired individuals to approach longevity asking ...
Breaking Medicine News(10 mins):Health News:Protect Dogs From Fleas and Ticks During the Summer 2Health News:Professor Develops Blood Test for Alzheimer’s Disease Risk 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 2Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 4Health News:Charon to receive 2014 Gene D. Cohen Award 2
... to hold sway on the degree of hangover one might ... has found. //Scottish researchers delved into this arena, and studied ... the clever lot benefit by being hangover less as compared ... ,The discomfort associated with a hangover, characterized by an unbearable ...
... Lilly Jaffe a six-year-old girl diagnosed with type 1 Diabetes ... of Chicago Medical Center on August 14. // Four days ... way to manufacturing insulin in her own body and ready ... started school., ,As she continued to do well, ...
... that severely ill malaria patients would benefit a lot ... Researchers from the Imperial College in London and experts ... replace fluids for children ill with malaria. ... the children who received the new treatment died, researchers ...
... report by Commonwealth Fund, employers are deducting health benefits ... cope with rising health care costs. // The higher ... to take individual insurance find it too expensive. Low-income ... may not have needed health care. ,An ...
... have great potentials in the fields of medicine and ... Dots (QDs) prove to be useful in advanced therapies ... ,A complete review of the latest literature and ... the nanotechnology website AzoNano. ,The review by Sandeep ...
... heart failure and men with treated prostate cancer are among ... Now, under new guidelines co-authored by a Hopkins cardiologist and ... Transplantation (ISHLT), they can and should be considered. ,“People ... have a chance to get a new heart,” says Stuart ...
Cached Medicine News:Health News:Molecular Medicine And Diabetes 2Health News:Molecular Medicine And Diabetes 3Health News:Molecular Medicine And Diabetes 4Health News:Molecular Medicine And Diabetes 5Health News:Molecular Medicine And Diabetes 6Health News:Molecular Medicine And Diabetes 7Health News:Most people applying for coverage end up not buying it 2Health News:Most people applying for coverage end up not buying it 3Health News:Now, Even Older Adults and Some Cancer Patients can go for Heart Transplantation 2
LUMIGAN® is a powerful eye drop medication for lowering IOP. IOP is short for intraocular pressure or eye pressure. LUMIGAN® is the first in a new class of medication....
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% is medication in the form of an eye drop that is used to lower the pressure inside your eye(s), also referred to as intraocular pressu...
Medicine Products: